Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis.
about
Bone damage in rheumatoid arthritis: mechanistic insights and approaches to preventionA combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis.The phosphoinositide 3-kinase isoform PI3Kβ regulates osteoclast-mediated bone resorption in humans and mice.Systemic but no local effects of combined zoledronate and parathyroid hormone treatment in experimental autoimmune arthritis.Blockade of IL-36 receptor signaling does not prevent from TNF-induced arthritis.Osteoclast activity modulates B-cell development in the bone marrowOsteoimmunology at the nexus of arthritis, osteoporosis, cancer, and infection.Cells of the synovium in rheumatoid arthritis. OsteoclastsErosive arthritis.Using hand bone mass measurements to assess progression of rheumatoid arthritis.Rheumatic diseases: the effects of inflammation on bone.Bone degeneration and recovery after early and late bisphosphonate treatment of ovariectomized wistar rats assessed by in vivo micro-computed tomography.Mechanisms of Disease: the link between RANKL and arthritic bone disease.Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.Longitudinal assessment of synovial, lymph node, and bone volumes in inflammatory arthritis in mice by in vivo magnetic resonance imaging and microfocal computed tomography.Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis: explorative analyses from the PREMIER studyGenistein aglycone reverses glucocorticoid-induced osteoporosis and increases bone breaking strength in rats: a comparative study with alendronateDifferential effects of biologic versus bisphosphonate inhibition of wear debris-induced osteolysis assessed by longitudinal micro-CT.Therapeutic targeting of osteoclast function and pathways.Osteoporosis drug therapy strategies in the setting of disease-modifying agents for autoimmune disease.Anti-TNF in rheumatoid arthritis: an overview.Bone as a Target Organ in Rheumatic Disease: Impact on Osteoclasts and Osteoblasts.Nordihydroguaiaretic acid inhibition of NFATc1 suppresses osteoclastogenesis and arthritis bone destruction in rats.Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial.RANKL increases the level of Mcl-1 in osteoclasts and reduces bisphosphonate-induced osteoclast apoptosis in vitro.RANKL: A therapeutic target for bone destruction in rheumatoid arthritis.Zoledronate for prevention of bone erosion in tophaceous gout: a randomised, double-blind, placebo-controlled trial.The anatomical basis for a novel classification of osteoarthritis and allied disorders.
P2860
Q34001621-9F172123-8C8E-458D-A60C-D7DEA9FE9170Q34413330-A65DB6E0-0B5A-4B8B-9AF2-27082CA59DF0Q35040987-65A8045C-9A92-46C5-9362-FBCB0115D649Q35122997-C9313AD0-ED99-43C2-9FB1-A8328B307AB8Q35222786-19FFBB97-9743-40CB-928A-3FE2E0D93A1BQ35348955-2574641A-F506-4BF0-9C25-1676363A63D5Q35572441-A9094135-EE7D-41FE-9D7C-C6846E824711Q35769060-AE31ADB8-B6AC-4A69-A702-D6EDBCEEC755Q35901078-787BD50E-BFE7-4E5E-B584-646C94707537Q36059378-1FC613E9-F0D4-4566-903E-D8A7CFBBDEC1Q36324975-4121A03B-EDD1-45F6-8FB1-08461D2B8B88Q36498921-168D9B2D-D648-4BB2-A18A-325DEBA695D5Q36577375-59B62364-E17F-44FF-B231-18EAACD6D469Q36860987-9187C88C-F1AD-4FAB-A341-7BE37D9C09CBQ37143025-71C7219E-F234-4217-8642-237C9EDD767EQ37210194-49F2BF33-583C-4723-8F6F-BF98EDE6F712Q37230770-4F015F65-8226-4A56-8140-B5DF71BEDAE2Q37342578-5FF1AF7C-DD5C-4636-83E1-3E93A9A46DDCQ37825905-5882902C-E9E2-4C74-A42C-D36A867BF97BQ38041419-12E4DA2E-B550-463C-9F90-28DAED2CFC99Q38344282-BF7C3D7D-0282-4EAA-B220-3D9A3F16FC5FQ38593977-8845DCDF-8367-43A4-AF3F-17068FB6D9BCQ39264023-D1629441-B392-4685-B2DF-732DA1E3D6FDQ40110226-DFCD3FC1-BE88-407A-BFB3-1103A7207A12Q42136336-0359015E-09F3-4EDA-A232-0823A02854C4Q50207113-FFAD34A7-2B6C-4D98-95F2-0E9F5E0BA436Q51237000-4FFD9601-DE06-49ED-90BA-33310B8D192DQ52848337-138FA858-13A5-4BEE-A001-B8EB30C36238
P2860
Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Zoledronic acid protects again ...... sis factor-mediated arthritis.
@en
Zoledronic acid protects again ...... sis factor-mediated arthritis.
@nl
type
label
Zoledronic acid protects again ...... sis factor-mediated arthritis.
@en
Zoledronic acid protects again ...... sis factor-mediated arthritis.
@nl
prefLabel
Zoledronic acid protects again ...... sis factor-mediated arthritis.
@en
Zoledronic acid protects again ...... sis factor-mediated arthritis.
@nl
P2093
P2860
P50
P356
P1476
Zoledronic acid protects again ...... sis factor-mediated arthritis.
@en
P2093
Birgit Görtz
Erika Reiter
Helga Bergmeister
Jürg Gasser
Kurt Redlich
Petra Herrak
Silvia Hayer
P2860
P304
P356
10.1002/ART.20384
P577
2004-07-01T00:00:00Z